Humoral complementomics – exploration of noninvasive complement biomarkers as predictors of renal cancer progression

IF 7.2 2区医学

Oncoimmunology Pub Date : 2024-03-13 DOI:10.1080/2162402x.2024.2328433

Margot Revel, Mikel Rezola Artero, Houcine Hamidi, Anne Grunenwald, Loris Blasco, Yann A. Vano, Stephane Marie Oudard, Rafael Sanchez-Salas, Petr Macek, Lara Rodriguez Sanchez, Xavier Cathelineau, Benoit Vedié, Catherine Sautes-Fridman, Wolf Herman Fridman, Lubka T. Roumenina, Marie-Agnes Dragon-Durey

引用次数: 0

Abstract

Despite the progress of anti-cancer treatment, the prognosis of many patients with solid tumors is still dismal. Reliable noninvasive biomarkers are needed to predict patient survival and therapy r...

查看原文本刊更多论文

体液补体组学--探索作为肾癌进展预测指标的非侵入性补体生物标志物

尽管抗癌治疗取得了进展，但许多实体瘤患者的预后仍然不容乐观。我们需要可靠的非侵入性生物标志物来预测患者的生存期和治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.